COMPANY
Ozempen.com
Ozempen.com: warning letter recipient for Semaglutide, as stated by public registers.
WARNING LETTER RECIPIENT
Received an FDA warning letter naming the peptide.
| Semaglutide | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet, 2024-06-24 Regulator FDA warning letters |
|---|
What a register states, not an endorsement or an accusation by this site. All companies.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.